MabVax Therapeutics Holdings, Inc. Share Price
Equities
MBVXQ
US55414P7024
Biotechnology & Medical Research
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
- USD | -.--% |
|
+10.05% | +182.21% |
2020 | MabVax Therapeutics Holdings, Inc. Went Out of Business | CI |
2020 | Second Amended Liquidation Plan & Disclosure Statment Approved for MabVax Therapeutics Holdings, Inc. | CI |
Sales 2016 | 148K 12.35M | Sales 2017 | - | Capitalization | 14.41M 1.2B |
---|---|---|---|---|---|
Net income 2016 | -17M -1.42B | Net income 2017 | -19M -1.58B | EV / Sales 2016 | 147 x |
Net Debt 2016 | 470K 39.21M | Net Debt 2017 | 2.48M 207M | EV / Sales 2017 | - |
P/E ratio 2016 |
-0.93
x | P/E ratio 2017 |
-0.25
x | Employees | - |
Yield 2016 * |
-
| Yield 2017 |
-
| Free-Float | 92.02% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 72 | - | |
Chief Tech/Sci/R&D Officer | 81 | 08/14/08 | |
Paul W. Maffuid
CTO | Chief Tech/Sci/R&D Officer | 68 | 08/14/08 |
Members of the board | Title | Age | Since |
---|---|---|---|
Chief Tech/Sci/R&D Officer | 81 | 08/14/08 |
1st Jan change | Capi. | |
---|---|---|
+182.21% | 213K | |
+16.45% | 122B | |
+19.15% | 113B | |
+2.62% | 22.66B | |
-16.26% | 21.34B | |
-39.57% | 16.92B | |
-13.99% | 16.68B | |
-16.29% | 16.61B | |
+3.15% | 13.62B | |
+21.93% | 11.04B |
- Stock Market
- Equities
- MBVXQ Stock